Study of an experimental drug for T-Cell Non-Hodgkin or Classic Hodgkin Lymphoma

What we are studying

The purpose of this study is to find the highest dose of CPI-613 that can be given in combination with the drug Bendamustine without causing severe side effects. Bendamustine is not an investigational drug and has been approved by the FDA for the treatment of Non-Hodgkin Lymphoma and Hodgkin Lymphoma. In addition, this study will also test the safety and effectiveness of CPI-613 when given in combination with Bendamustine.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosis of T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma

What is involved

  • Multiple four-week cycles of treatment with CPI-613 and Bendamustin

Compensation

None

Contact Information

Study Coordinator
Jennifer Thomas
Email
jethomas@wakehealth.edu
Phone
336-713-6914

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.